Drug intelligence / Profile preview

UI112

Development stage: Preclinical
Lead developer: Korea United Pharm
Modality: Small Molecules

Overview

UI112 is a small molecule drug candidate being developed by Korea United Pharm for the treatment of obesity. It is classified as an Incrementally Modified Drug (IMD), a regulatory category in South Korea for medications that improve upon existing drugs through new formulations, combinations, or delivery methods. As of early 2024, UI112 is in the preclinical stage of development. While the specific active ingredients and molecular targets have not been publicly disclosed, the project aims to optimize existing anti-obesity pharmacotherapy to enhance efficacy, safety, or patient convenience.

Beyond the preview

Go deeper on UI112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI112.

Explore the full profile